此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估 VT3989 在转移性实体瘤患者中的研究,该肿瘤富含 NF2 基因突变的肿瘤

2026年11月12日 更新者:Vivace Therapeutics, Inc

评估 VT3989 在难治性局部晚期或转移性实体瘤患者中的安全性、耐受性和 PK 的第 1 期、多中心、开放标签研究,富含 NF2 基因突变的肿瘤

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

研究概览

详细说明

Dose escalation (Part 1) will employ a traditional 3 + 3 design to assess safety of VT3989 in patients with metastatic solid tumors or mesothelioma. The 3 + 3 design will be implemented until the MTD or recommended phase 2 dose(s) and schedule(s) are determined. The MTD is defined as the highest dose level at which < 33% of patients experience a dose limiting toxicity (DLT) during the first cycle of the study (Cycle 1).

Dose Expansion (Part 2) will further evaluate the safety and assess preliminary antitumor activity at the recommended phase 2 dose(s) and schedule(s) with up to 6 cohorts. Expansion cohorts 1 and 2 will enroll patients with mesothelioma of any site origin with or without NF2 mutations. Expansion cohort 3 will enroll non-pleural mesothelioma patients. Expansion cohort 4 will enroll solid tumor patients with clearly inactivating NF2 mutations/alterations or YAP/TAZ gene rearrangements. Cohort 5 will enroll pleural mesothelioma patients.

Combination part (Part 3) includes three cohorts. Cohort A will enroll mesothelioma patients who will receive VT3989 in combination with immunotherapy (nivolumab plus ipilimumab). Cohort B will enroll NSCLC patients whose tumors have exon 19 deletion or exon 21 L858R mutation and will receive VT3989 in combination with targeted therapy (Osimertinib). Cohort C will enroll pleural mesothelioma patients who will receive VT3989 in combination with chemotherapy (pemetrexed plus carboplatin).

研究类型

介入性

注册 (估计的)

474

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Victoria
      • Clayton、Victoria、澳大利亚、3168
      • Melbourne、Victoria、澳大利亚、3000
        • 招聘中
        • Peter MacCullum Cancer Centre
        • 接触:
    • Western Australia
      • Nedlands、Western Australia、澳大利亚、6009
        • 终止
        • Linear Clinical Research
    • California
      • San Francisco、California、美国、94158
        • 招聘中
        • UCSF Helen Diller Family Comprehensive Cancer Center
        • 接触:
    • Illinois
      • Chicago、Illinois、美国、60637
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • 招聘中
        • Massachusetts General Hospital
        • 接触:
      • Boston、Massachusetts、美国、02215
    • Minnesota
      • Minneapolis、Minnesota、美国、55455
        • 招聘中
        • M Health Fairview University of Minnesota Medical Center
        • 接触:
    • New York
      • New York、New York、美国、10065
        • 招聘中
        • Memorial Sloan Kettering Cancer Center
        • 接触:
    • Texas
      • Houston、Texas、美国、77030
      • San Antonio、Texas、美国、78229
        • 招聘中
        • NEXT Oncology
        • 接触:
    • Virginia
      • Arlington、Virginia、美国、22201
        • 招聘中
        • Virginia Cancer Specialists, PC
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Part 3 Combination Cohort A: Patients with pathologically diagnosed, metastatic or unresectable malignant mesothelioma (including both pleural and non-pleural) who have not received systemic therapy.
  • Part 3 Combination Cohort B: Patients with pathologically diagnosed incurable locally advanced (inoperable or recurrent), or metastatic NSCLC with exon 19 deletions or exon 21 L858R mutations, with or without prior treatment with Osimertinib.
  • Part 3 Combination Cohort C: Patients with pathologically diagnosed metastatic or unresectable malignant pleural mesothelioma who have not received systemic chemotherapy.
  • Part 1: Evaluable or measurable disease per RECIST v1.1 or mRECIST
  • Part 2 and 3: Measurable disease per RECIST v1.1 for non-pleural mesothelioma or other solid tumors or modified RECIST v1.1 for malignant pleural mesothelioma. mRECIST may be used for pleural extension of non-pleural mesothelioma or for mixed pleural and peritoneal (or other) mesothelioma.
  • ECOG: 0-1.
  • Adequate organ functions, including the liver, kidneys, and hematopoietic system.

Exclusion Criteria:

  • Active brain metastases or primary CNS (central nervous system) tumors.
  • History of leptomeningeal metastases
  • Active or chronic, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
  • Known HIV positive or active Hepatitis B or Hepatitis C
  • Clinically significant cardiovascular disease and prior exposure to cardiotoxic agents.
  • Corrected QT (QTcF) interval > 470 msec (using Fridericia's correction formula).
  • Additional active malignancy that may confound the assessment of the study endpoints
  • Women who are pregnant or breastfeeding
  • Unwilling or unable to use highly effective contraceptive measures.
  • Prior treatment with TEAD inhibitor, except for EHE patients.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:VT3989 Dose Escalation [Not Recruiting]

VT3989 dosed orally in 21 or 28 day cycles. Patients will be enrolled into escalating dose levels during the Dose Escalation Phase

25, 50, 100, 150 or 200 mg for oral administration.

实验性的:Dose Expansion [Not Recruiting]

VT3989 dosed in 21 or 28 day cycles in patients with refractory metastatic solid tumors or mesothelioma.

25, 50, 100, 150 or 200 mg for oral administration.

实验性的:Combination [Recruiting]

For Cohort A and B, VT3989 dosed in 28 day cycles in patients with metastatic solid tumors or mesothelioma, in combination with immunotherapy (nivolumab/ipilimumab) or targeted therapy (osimertinib). For Cohort C, VT3989 dosed in 21 day cycles in patients with mesothelioma in combination with chemotherapy (pemetrexed+carboplatin) for 4-6 cycles, then continuing VT3989 as monotherapy on 28-day cycle.

25, 50, 100, 150 or 200 mg for oral administration.

Nivolumab infusion - 360 mg every 3 weeks, 30-minute intravenous infusion

Ipilimumab infusion - 1 mg/kg every 6 weeks, 30-minute intravenous infusion

40 or 80 mg tablets for oral administration

Pemetrexed infusion: 500 mg/m2 intravenous infusion Carboplatin infusion: AUC 5.0 intravenous infusion

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Occurrence of Dose Limiting Toxicity
大体时间:over the first 21 days of dosing

Incidence of Adverse and Serious Adverse Events

over the first 21 days of dosing
Occurrence of General Toxicity
大体时间:through study completion, an average of 30 months

Incidence of Adverse and Serious Adverse Events, Discontinuations due to Adverse Events and general safety evaluations

through study completion, an average of 30 months

次要结果测量

结果测量
措施说明
大体时间
Tumor Response
大体时间:through study completion, an average of 30 months

Determined by RECIST v1.1 or modified RECIST v1.1

through study completion, an average of 30 months
Pharmacokinetic Evaluation - Cmax
大体时间:for first 6 cycles

Peak plasma concentration of VT3989

for first 6 cycles
Pharmacokinetic Evaluation - Tmax
大体时间:for first 6 cycles

Time to reach peak plasma concentration of VT3989

for first 6 cycles
Pharmacokinetic Evaluation - Half-life
大体时间:for first 6 cycles

Time required for the plasma concentration of VT3989 to reduce by half after reaching peak

for first 6 cycles
Overall survival
大体时间:At 6, 12, 18 and 24 months

The overall survival of the enrolled patients from starting VT3989 treatment

At 6, 12, 18 and 24 months
Progression free survival
大体时间:At 6, 12, 18 and 24 months

The progression free survival of the enrolled patients from starting VT3989 treatment

At 6, 12, 18 and 24 months
Quality of life assessment (Part 2, expansion cohort 3, 4, and 5)
大体时间:Through study completion, an average of 30 months

Assessing the Quality of life changes via patient reported outcomes

Through study completion, an average of 30 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Neelesh Sharma, MD、Vivace Therapeutics

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年3月24日

初级完成 (估计的)

2029年11月2日

研究完成 (估计的)

2030年3月2日

研究注册日期

首次提交

2020年12月5日

首先提交符合 QC 标准的

2020年12月10日

首次发布 (实际的)

2020年12月11日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅